Company Overview - The Cooper Companies, Inc. (COO) has a market capitalization of $15.8 billion and specializes in medical devices, particularly contact lenses and women's health care solutions through its CooperVision and CooperSurgical segments [1] - The company is classified as a "large-cap" stock, serving healthcare professionals and distributors globally [2] Stock Performance - COO shares have declined 19.6% from their 52-week high of $100.47, but have increased 19.3% over the past three months, outperforming the Nasdaq Composite's 8.1% increase during the same period [3] - Year-to-date, COO stock is down 12.2%, lagging behind the Nasdaq's 22.5% surge, and has decreased 18.5% over the past 52 weeks compared to the Nasdaq's 20.2% return [4] Financial Results - Following the Q4 2025 results released on December 4, COO shares rose 5.7%, with adjusted EPS of $1.15 and revenue of $1.07 billion, both exceeding consensus expectations [5] - The company provided a positive outlook for fiscal 2026, projecting adjusted EPS guidance of $4.45 - $4.60 and free cash flow of $575 million - $625 million, with a long-term goal of generating over $2.2 billion in free cash flow from 2026 to 2028 [5] Analyst Sentiment - Despite underperformance compared to rival Intuitive Surgical, which has seen a YTD increase of 6.5%, analysts maintain a moderately optimistic view on Cooper, with a consensus rating of "Moderate Buy" from 17 analysts [6] - The mean price target for COO stock is $89.62, indicating a potential upside of nearly 11% from current levels [6]